Related Experiment Videos
Centrifugal leukocyte apheresis for ulcerative colitis
1Third Department of Internal Medicine, Asahikawa Medical College, Japan.
Summary
Leukocyte apheresis effectively treats corticosteroid-resistant ulcerative colitis, achieving remission in 78.3% of patients. This procedure offers a safe alternative for managing severe ulcerative colitis when steroids fail.
Area of Science:
- Gastroenterology
- Immunology
- Medical Technology
Background:
- Corticosteroids are standard treatment for ulcerative colitis but often fail in relapsed or refractory cases.
- Long-term corticosteroid use is associated with significant adverse effects.
- Previous pilot studies suggested leukocyte apheresis as a potential therapy for corticosteroid-resistant ulcerative colitis.
Purpose of the Study:
- To evaluate the clinical efficacy of centrifugal leukocyte apheresis in patients with corticosteroid-resistant ulcerative colitis.
- To confirm the safety and effectiveness of this apheresis technique in a larger patient cohort.
Main Methods:
- Twenty-three patients with severely active, corticosteroid-resistant ulcerative colitis underwent centrifugal leukocyte apheresis.
- Clinical remission was assessed using the clinical activity index within four weeks post-procedure.
- Colonoscopic and histological examinations were performed to confirm treatment outcomes.
Main Results:
- Eighteen out of twenty-three patients (78.3%) achieved clinical remission within four weeks of leukocyte apheresis.
- Colonoscopic and histological assessments corroborated the clinical findings, indicating significant improvement.
- The procedure was well-tolerated, with no major adverse events reported during therapy.
Conclusions:
- Centrifugal leukocyte apheresis is a highly effective treatment for corticosteroid-resistant ulcerative colitis.
- This apheresis method provides a safe and beneficial therapeutic option for patients with severe ulcerative colitis refractory to standard corticosteroid treatment.